Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.61 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.61 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.61 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.61 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.61 |
| ▸ | GPR183 | P32249 | 1/20 | 0.61 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.61 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.52 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | TACR2 | P21452 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036574 | 0.92 | S1PR1 (0.56) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL15190569 | 0.86 | THRA (0.50) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL15960550 | 0.83 | LIPG (0.45) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL1687901 | 0.81 | TSHR (0.40) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL901600 | 0.81 | TNNC1 (0.47) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL2723128 | 0.80 | TNNC1 (0.50) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL2726354 | 0.80 | S1PR1 (0.51) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL8496007 | 0.79 | TNNC1 (0.50) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL1170931 | 0.79 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL1170888 | 0.79 | ALDH1A1 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004747-A | Synthesis method of fingolimod hydrochloride | 杭州科耀医药科技有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-120004747-A | Synthesis method of fingolimod hydrochloride | 杭州科耀医药科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-2632889-B1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD (IL) | 2018-08-29 | — | — | EP | disclosed |
| EP-3092222-B1 | IMPROVED FINGOLIMOD PROCESS | EMCURE PHARMACEUTICALS LTD (IN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3092222-A1 | IMPROVED FINGOLIMOD PROCESS | Emcure Pharmaceuticals Limited (IN) | 2016-11-16 | — | — | EP | disclosed |
| US-9216943-B2 | Preparation of fingolimod and its salts | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-22 | — | — | US | disclosed |
| US-9216943-B2 | Preparation of fingolimod and its salts | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-22 | — | — | US | disclosed |
| US-9216943-B2 | Preparation of fingolimod and its salts | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-22 | — | — | US | disclosed |
| WO-2015107548-A1 | IMPROVED FINGOLIMOD PROCESS | EMCURE PHARMACEUTICALS LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| CN-104292115-A | New synthetic method of fingolimod hydrochloride | UNIV YANTAI | 2015-01-21 | — | — | CN | disclosed |
| US-8735627-B2 | Intermediate compounds and process for the preparation of fingolimod | MAPI PHARMA LTD. (IL) | 2014-05-27 | — | — | US | disclosed |
| EP-2702034-A2 | PREPARATION OF FINGOLIMOD AND ITS SALTS | Dr. Reddy's Laboratories Ltd. (IN) | 2014-03-05 | — | — | EP | disclosed |
| EP-2632889-A2 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | Mapi Pharma Limited (IL) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2013-08-22 | — | — | US | disclosed |
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2013-08-22 | — | — | US | disclosed |
| WO-2012146980-A2 | PREPARATION OF FINGOLIMOD AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012056458-A2 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012041707-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON BV (NL) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041405-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041359-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | S1PR2, S1PR4, S1PR3 | S1PR1 4/4885S1PR4 2/4885S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.